Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.
Rahaghi FF, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, King C, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White RJ, Hill NS.
Rahaghi FF, et al. Among authors: balasubramanian vp.
Pulm Circ. 2022 Apr 7;12(2):e12055. doi: 10.1002/pul2.12055. eCollection 2022 Apr.
Pulm Circ. 2022.
PMID: 35514769
Free PMC article.